Versant Capital Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $375K | Sell |
15,577
-2,164
| -12% | -$56.6K | 0.03% | 394 |
|
|
2026
Q1 | $498K | Buy |
17,741
+1,446
| +9% | +$38.5K | 0.05% | 258 |
|
|
2025
Q4 | $406K | Sell |
16,295
-15,094
| -48% | -$381K | 0.05% | 264 |
|
|
2025
Q3 | $800K | Buy |
31,389
+20,167
| +180% | +$498K | 0.11% | 108 |
|
|
2025
Q2 | $272K | Sell |
11,222
-8,224
| -42% | -$192K | 0.04% | 361 |
|
|
2025
Q1 | $493K | Buy |
19,446
+12,647
| +186% | +$331K | 0.08% | 161 |
|
|
2024
Q4 | $180K | Buy |
6,799
+2,365
| +53% | +$64.2K | 0.04% | 196 |
|
|
2024
Q3 | $128K | Buy |
4,434
+952
| +27% | +$27.8K | 0.03% | 200 |
|
|
2024
Q2 | $97.4K | Sell |
3,482
-173
| -5% | -$4.76K | 0.02% | 214 |
|
|
2024
Q1 | $101K | Sell |
3,655
-1,118
| -23% | -$31K | 0.03% | 186 |
|
|
2023
Q4 | $137K | Buy |
4,773
+523
| +12% | +$15.8K | 0.04% | 155 |
|
|
2023
Q3 | $141K | Buy |
4,250
+5
| +0.1% | +$177 | 0.04% | 146 |
|
|
2023
Q2 | $156K | Buy |
4,245
+107
| +3% | +$4.17K | 0.05% | 145 |
|
|
2023
Q1 | $169K | Buy |
4,138
+1,036
| +33% | +$44.7K | 0.06% | 130 |
|
|
2022
Q4 | $159K | Hold |
3,102
| – | – | 0.06% | 119 |
|
|
2022
Q3 | $136K | Buy |
3,102
+39
| +1% | +$1.9K | 0.05% | 128 |
|
|
2022
Q2 | $161K | Sell |
3,063
-276
| -8% | -$14.1K | 0.06% | 112 |
|
|
2022
Q1 | $173K | Buy |
3,339
+276
| +9% | +$14.3K | 0.06% | 120 |
|
|
2021
Q4 | $181K | Sell |
3,063
-3,000
| -49% | -$149K | 0.06% | 113 |
|
|
2021
Q3 | $261K | Sell |
6,063
-342
| -5% | -$15.2K | 0.09% | 85 |
|
|
2021
Q2 | $251K | Sell |
6,405
-1,746
| -21% | -$67.9K | 0.09% | 84 |
|
|
2021
Q1 | $295K | Buy |
8,151
+3,006
| +58% | +$107K | 0.11% | 83 |
|
|
2020
Q4 | $189K | Sell |
5,145
-489
| -9% | -$17.9K | 0.07% | 95 |
|
|
2020
Q3 | $196K | Buy |
5,634
+28
| +0.5% | +$982 | 0.09% | 94 |
|
|
2020
Q2 | $173K | Sell |
5,606
-63
| -1% | -$2.14K | 0.08% | 100 |
|
|
2020
Q1 | $175K | Buy |
5,669
+167
| +3% | +$5.69K | 0.09% | 89 |
|
|
2019
Q4 | $204K | Sell |
5,502
-731
| -12% | -$26K | 0.1% | 83 |
|
|
2019
Q3 | $212K | Sell |
6,233
-258
| -4% | -$9.38K | 0.1% | 81 |
|
|
2019
Q2 | $266K | Sell |
6,491
-1,878
| -22% | -$74.6K | 0.12% | 68 |
|
|
2019
Q1 | $337K | Sell |
8,369
-43
| -0.5% | -$1.72K | 0.14% | 67 |
|
|
2018
Q4 | $348K | Buy |
8,412
+1,318
| +19% | +$54.7K | 0.16% | 65 |
|
|
2018
Q3 | $296K | Sell |
7,094
-10
| -0.1% | -$385 | 0.12% | 71 |
|
|
2018
Q2 | $244K | Sell |
7,104
-102
| -1% | -$3.49K | 0.1% | 83 |
|
|
2018
Q1 | $242K | Sell |
7,206
-187
| -3% | -$6.43K | 0.1% | 89 |
|
|
2017
Q4 | $254K | Buy |
7,393
+537
| +8% | +$18.3K | 0.1% | 89 |
|
|
2017
Q3 | $232K | Buy |
6,856
+96
| +1% | +$3.08K | 0.13% | 71 |
|
|
2017
Q2 | $215K | Sell |
6,760
-165
| -2% | -$5.2K | 0.12% | 74 |
|
|
2017
Q1 | $224K | Hold |
6,925
| – | – | 0.12% | 72 |
|
|
2016
Q4 | $213K | Sell |
6,925
-306
| -4% | -$9.34K | 0.12% | 71 |
|
|
2016
Q3 | $232K | Sell |
7,231
-140
| -2% | -$4.68K | 0.13% | 70 |
|
|
2016
Q2 | $246K | Sell |
7,371
-59
| -0.8% | -$1.88K | 0.15% | 61 |
|
|
2016
Q1 | $208K | Sell |
7,430
-614
| -8% | -$17.5K | 0.13% | 68 |
|
|
2015
Q4 | $246K | Buy |
+8,044
| New | +$253K | 0.15% | 57 |
|
Other funds holding PFE
Versant Capital Management's PFE Position: Q2 2026 in Review
Versant Capital Management reduced its Pfizer (PFE) stake by 12% in Q2 2026, selling an estimated $56.6K and leaving 15,577 shares worth $375K. The position accounts for 0.03% of the portfolio, ranked #394.
Versant Capital Management first reported a position in PFE in Q4 2015 and has held it in 43 quarters since. The position peaked at $800K in Q3 2025. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Versant Capital Management held 15,577 shares of Pfizer worth $375K as of Q2 2026.
- Versant Capital Management sold 2,164 Pfizer shares in Q2 2026, an estimated $56.6K.
- Pfizer made up 0.03% of Versant Capital Management's portfolio in Q2 2026, its #394 holding.
- Versant Capital Management first reported a position in Pfizer in Q4 2015 and has held it in 43 quarters since.
- Versant Capital Management's Pfizer position peaked at $800K in Q3 2025.
- 2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.